W

Waikato Hospital | Cardiology Clinical Trials Unit

Research site
(Unclaimed)
Location
14 Horne Street, Hamilton, New South Wales, New Zealand
Site insights

Top conditions

Ulcer (22 trials)

Ulcerative Colitis (20 trials)

Colitis (20 trials)

Arthritis (15 trials)

Crohn Disease (13 trials)

Top treatments

Upadacitinib
Apremilast
Filgotinib
ABT-494
Etrolizumab
Ontamalimab
Vincristine
CP-690,550
cyclophosphamide
Guselkumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

56 of 223
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

The purpose of this study is the evaluation of the performance, safety and efficacy of Hydra Aortic valve in real-world patients. Following initial i...

Active, not recruiting
Aortic Valve Stenosis
Device: Hydra TAVI

The purpose of this study is to determine whether Fractional flow reserve (FFR, (coronary pressure wire-based index for assessing the ischemic potent...

Active, not recruiting
Coronary Disease
Coronary Stenosis
Procedure: FFR guided PCI
Device: Resolute Integrity Stent

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting
Psoriatic Arthritis
Biological: Risankizumab
Biological: Placebo

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting
Psoriatic Arthritis (PsA)
Biological: Risankizumab
Biological: Placebo

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plu...

Active, not recruiting
Diffuse Large B-Cell Lymphoma
Drug: Polatuzumab vedotin Placebo
Drug: Vincristine Placebo

It is hypothesized that significantly more patients would prefer oral decitabine/cedazuridine to subcutaneous (SC) azacitidine (AZA) due to several f...

Enrolling
Patient Preference
Leukemia, Myeloid, Acute
Drug: Subcutaneous azacitidine
Drug: Oral decitabine/cedazuridine

The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and v...

Active, not recruiting
Rheumatoid Arthritis
Drug: Upadacitinib
Drug: Placebo for Adalimumab

This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus...

Active, not recruiting
Psoriatic Arthritis
Drug: Adalimumab
Drug: Placebo to Adalimumab

The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus plac...

Active, not recruiting
Psoriatic Arthritis
Drug: Placebo
Drug: Upadacitinib
Locations recently updated

The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmo...

Enrolling
Systemic Sclerosis With Lung Involvement
Idiopathic Pulmonary Fibrosis
Drug: Vixarelimab
Drug: Placebo

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in pa...

Active, not recruiting
Cystic Fibrosis
Drug: VX-121/TEZ/D-IVA

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance tr...

Active, not recruiting
FIGO Stage III-IV
Newly Diagnosed
Drug: Rucaparib
Drug: Placebo Oral Tablet

This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype...

Enrolling
Scleroderma, Systemic
Drug: Placebo
Drug: Avenciguat (BI 685509)

This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherap...

Active, not recruiting
Renal Cell Cancer
Drug: Axitinib (AG-013736)
Drug: Avelumab (MSB0010718C)

This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult p...

Active, not recruiting
Alpha 1-Antitrypsin Deficiency
Drug: Belcesiran
Other: Placebo

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Other: Placebo
Drug: Guselkumab Dose 1

This Phase 2 study is a two-stage, serial cohort dose escalation and expansion study of a single 30-minute (IV) infusion of HBI-3000 for the conversi...

Enrolling
Atrial Fibrillation
Drug: HBI-3000
Drug: Placebo

Trial sponsors

AbbVie logo

AbbVie (17 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems